GINA RAGUSA: Open Payments
NPI 1144575432 · GONZALES, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,798 in 159 payments from 19 companies in 2025. Trend: 2023 $1,854 · 2024 $2,288 · 2025 $2,798
Food & beverage: $2,798
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 63 | $795 |
| Madrigal Pharmaceuticals | 16 | $369 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $282 |
| Regeneron Healthcare Solutions, Inc. | 7 | $243 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 8 | $146 |
| Phathom Pharmaceuticals, Inc. | 7 | $144 |
| Aimmune Therapeutics, Inc. | 5 | $118 |
| QOL Medical, LLC | 5 | $109 |
| Intercept Pharmaceuticals, Inc. | 6 | $109 |
| Ipsen Biopharmaceuticals, Inc | 4 | $103 |
Products named: RINVOQ, REZDIFFRA, ENTYVIO, DUPIXENT, VOQUEZNA, Sucraid, OCALIVA, IQIRVO.
Industry payments across LA — which companies pay providers there.
